Ds8201-A-U301- A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial Of Ds-8201A, An Anti-Her2-Antibody Drug Conjugate (Adc), Versus Treatment Of Investigator's Choice For Her2-Positive, Unresectable And/Or Metastatic Breast Cancer Subje
Posted Date: Oct 1, 2019
- Investigator: Mahmoud Charif
- Specialties: Breast Cancer, Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to compare the progression-free survival (PFS) benefit of trastuzumab deruxtecan to investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with T-DM1.
Criteria:
To Be Eligible You Must Be Diagnosed With Metastatic Or Unresectable Breast Cancer, >18 Years Of Age, No Uncontrolled Cardiovascular Disease, Nonpregnant And Nonbreastfeeding
Keywords:
Breast, Cancer, Oncology
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com